Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
Douglas L. Mann(Washington University in St. Louis), Thomas R. Fleming(University of Washington), John J.V. McMurray(University of Glasgow), Luigi Tavazzi(Maria Cecilia Hospital), Wilson S. Colucci(Boston University), Lars Køber(University of Copenhagen), Anders Waldenström(Cornell University), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Milton Packer(Baylor University Medical Center), Marshelle Warren(Amgen (United States)), Markku S. Nieminen(Cornell University), Jeffrey Borer(Cornell University), Jacques Djian(Cornell University), Karl Swedberg(Brigham and Women's Hospital), Peter Liu(Genomic Health (United States)), Dirk Jan van Veldhuisen(University of Groningen), Henry Krum(Australian Regenerative Medicine Institute), Arthur M. Feldman(Johns Hopkins University), Helmut Drexler(Freie Universität Berlin), Arne Westheim(Cornell University)
Cited by 1,228
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k